Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.38 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | ACHE | P22303 | 3/20 | 0.34 |
| ▸ | BCHE | P06276 | 2/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16504486 | 1.00 | MAPT (0.39) | MAPTNPSR1PTGS2HCAR3HTT | |
| SCHEMBL29404113 | 0.90 | MAPT (0.41) | MAPTNPSR1PTGS2HCAR3HTT | |
| SCHEMBL14692478 | 0.77 | CASP6 (0.57) | HCAR3TSHR | |
| SCHEMBL29404544 | 0.76 | MAPT (0.46) | MAPTHCAR3HTTATMKMT2A | |
| SCHEMBL11765920 | 0.75 | TSHR (0.57) | MAPTNPSR1PTGS2HCAR3KMT2A | |
| SCHEMBL11765935 | 0.75 | TSHR (0.57) | MAPTNPSR1PTGS2HCAR3KMT2A | |
| SCHEMBL14691580 | 0.74 | KMT2A (0.49) | MAPTHTTATMKMT2AALDH1A1 | |
| SCHEMBL14691578 | 0.74 | KMT2A (0.49) | MAPTHTTATMKMT2AALDH1A1 | |
| SCHEMBL30706306 | 0.74 | LMNA (0.55) | MAPTNPSR1PTGS2HCAR3HTT | |
| SCHEMBL585127 | 0.74 | ALDH1A1 (0.49) | MAPTNPSR1PTGS2HCAR3HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9108981-B2 | Cyclic P1 linkers as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-18 | — | — | US | disclosed |
| US-20150057262-A1 | CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS | NAVY, SECRETARY OF THE UNITED STATES OF AMERICA | 2015-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057262-A1 | CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS | F11, F12, F13A1 | MAPT 673/4885NPSR1 1265/4885PTGS2 1745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.